Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Roche Holding AG

Market Cap 258B 323B 280B 242B 452B 30,925B 462B 3,082B 1,193B 14,907B 1,212B 1,186B 51,831B P/E Ratio 2026 *
17.4x
P/E Ratio 2027 * 16.2x
Enterprise Value 269B 336B 291B 252B 470B 32,159B 480B 3,205B 1,241B 15,502B 1,261B 1,234B 53,900B EV / Sales 2026 *
4.29x
EV / Sales 2027 * 4.02x
Free-Float
88.78%
Yield 2026 *
3.1%
Yield 2027 * 3.17%
1 day+0.62%
Current month+0.93%
3 months-1.42%
6 months+2.33%
Current year-0.88%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+3.95% - - 324B
+1.64%+3.01%+43.35%+160.30% 1,013B
+0.52%+5.13%+54.50%+50.02% 574B
+0.25%+0.35%+17.87%+63.89% 397B
+0.85%+0.18%+24.50%+14.78% 280B
+2.10%+4.92%+25.30%+33.80% 273B
+3.80%+1.48%+20.19%+61.36% 182B
-0.19%-0.46%-45.32%-48.35% 194B
+3.35%-2.69%+15.00%+61.44% 151B
+2.05%+2.02%+7.07%-34.31% 146B
Average +1.48%+2.42%+18.05%+40.33% 356.75B
Weighted average by Cap. +1.26%+3.95%+29.36%+73.50%

Financials

2026 *2027 *
Net sales 62.58B 78.23B 67.89B 58.64B 110B 7,491B 112B 747B 289B 3,611B 294B 287B 12,555B 65.13B 81.42B 70.66B 61.03B 114B 7,796B 116B 777B 301B 3,758B 306B 299B 13,067B
Net income 15.16B 18.95B 16.44B 14.2B 26.53B 1,814B 27.09B 181B 70B 875B 71.13B 69.6B 3,041B 16.22B 20.28B 17.6B 15.2B 28.4B 1,942B 28.99B 193B 74.91B 936B 76.12B 74.48B 3,254B
Net Debt 10.31B 12.89B 11.19B 9.66B 18.06B 1,234B 18.43B 123B 47.63B 595B 48.4B 47.36B 2,069B 3.44B 4.3B 3.73B 3.22B 6.02B 412B 6.14B 41.01B 15.88B 198B 16.13B 15.79B 690B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
11/06/26 325.30 CHF +0.43% 1,371,862
10/06/26 323.90 CHF +1.60% 1,329,930
09/06/26 318.80 CHF -1.21% 1,844,589
08/06/26 322.70 CHF -1.35% 626,869
05/06/26 327.10 CHF +0.77% 1,148,657
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
323.90CHF
Average target price
360.76CHF
Spread / Average Target
+11.38%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!